
Novo-backed ReViral acquired by Pfizer
Novo Ventures-backed ReViral, a biotech company treating respiratory syncytial virus, has been acquired by Pfizer for USD 525m.
Novo co-led ReViral's USD 55m Series B in July 2018 alongside New Leaf Venture Partners.
CR-CP Life Sciences led a later USD 44m Series C in August 2020, with Andera Partners and OrbiMed earlier leading a USD 21m Series A.
The USD 525m price tag includes upfront and development milestones.
Novo said that the deal demonstrates commercial interest from big pharma in infectious diseases, which it describes as an area of high unmet need.
ReViral is a clinical-stage biopharma company focused on discovering, developing and commercialising treatments for respiratory syncytial virus (RSV).
The virus infects around 64 million people a year, resulting in 160,000 deaths globally.
ReViral's lead drug, sisunatovir, is an orally administered inhibitor designed to block the fusion of the virus to the host cell. It significantly reduced viral load in a phase 2 human challenge study in healthy adults and is currently in phase 2 clinical development in infants.
Pfizer says it believes annual revenue for these programmes could exceed USD 1.5bn a year.
Advisors
Pfizer - Clifford Chance (legal)
ReViral - Centerview and BofA Securities (M&A); Goodwin Procter (legal).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds